Enanta Pharmaceuticals Delivers Key Updates on Virology and Immunology Programs While Reporting Fiscal Year 2024 Results Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company specializing in small molecule drugs for virology and immunology, announced its financial results for the…
ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on rebalancing the inflammatory response to treat rare and acute inflammatory diseases, has announced the appointment of Dr. Lewis T. “Rusty” Williams, M.D., Ph.D., as Chairman of…
Omeros Corporation (Nasdaq: OMER) has shared an update on its ongoing efforts to resubmit the biologics license application (BLA) for narsoplimab, its first-in-class antibody targeting MASP-2, a key enzyme in the lectin pathway of complement activation. Narsoplimab is being developed…
Pfizer Inc. (NYSE: PFE) has announced the appointment of Chris Boshoff, M.D., PhD, as its new Chief Scientific Officer and President of Research & Development, effective January 1, 2025. Dr. Boshoff, who most recently served as Pfizer’s Chief Oncology Officer…
Bio-Techne Corporation (NASDAQ: TECH), a leading global provider of innovative tools and bioactive reagents for research and clinical diagnostics, has announced a strategic partnership with Leader Life Sciences. Under this agreement, Leader Life Sciences will serve as a distributor for…
The World Health Organization’s (WHO) first-ever Investment Round reached a pivotal milestone at the G20 Leaders’ Summit in Rio de Janeiro. Chaired by Brazilian President H.E. Luiz Inácio Lula da Silva, the event saw heads of state and government voice…
CVS Health® (NYSE: CVS) announced the addition of four new members to its Board of Directors: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman. These appointments follow collaborative discussions with Glenview Capital Management. “Our discussions with Glenview have reinforced…
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced positive 18-month results from the Phase 2 PROPEL 2 trial evaluating infigratinib as a treatment for children with achondroplasia. The findings, published today in the New…
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced…
AstraZeneca today announced a $3.5 billion investment in the United States to expand the company’s research and manufacturing footprint by the end of 2026. This includes $2 billion in new investments creating more than 1,000 new high-skilled jobs that will…
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the close of an oversubscribed $84…
Reverb Therapeutics, a leader harnessing the body’s immune system and cytokine signaling to treat life-threatening diseases, announced it has launched a collaboration with Royalmount Laboratories, based in Montreal, as Reverb works towards lead selection and pre-IND enabling work on its…